Table 2.
Brief history of the case series.
| Case | Age | Gender | Past history | Episode | Corneal lesion, laterality | Long-term medication (preservatives)/laterality | Duration | Last-added medication (preservatives)/laterality | Duration | HSV culture | Managementa |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 26 | M | DED | 1st | Type IV, ou | Timolol (BAK)/ou | 1 year | NA | Negative | A, B | |
| 2 | 67 | M | DED | 1st | Type II, od | Pilocarpine (BAK)/od | 1 year | Dorzolamide (BAK)/ou | 1 month | Negative | C |
| 3 | 60 | F | DM | 1st | Type II, os | Latanoprost (BAK)/ou | 14 years | NA | Negative | A, F | |
| 4 | 70 | F | – | 1st | Type II, os | Latanoprost (BAK)/ou | 6 years | NA | Negative | A, C, E | |
| 5 | 93 | M | DED | 1st | Type V, ou | Dorzolamide/timolol (BAK)/ou | 1 year | NA | Negative | A | |
| 6 | 75 | M | DED | 1st | Type II, ou | Carteolol (BAK)/ou | 7 years | Latanoprost (BAK)/ou | 3 months | Negative | A, C, E |
| 7 | 69 | M | DED | 1st | Type II, os | Latanoprost (BAK)/os | 1 year | NA | Negative | B, C | |
| 8 | 78 | M | DED, DM | 1st | Type I, os | Latanoprost (BAK)/ou, dorzolamide/timolol (BAK)/ou | 3.5 years | NA | NA | A,C, E | |
| 2nd | Type III, od | Brimonidine (purite)/ou | 8 months | NA | A, C, E | ||||||
| 9 | 74 | F | SS | 1st | Type II, ou | Carteolol(BAK)/ou | 1.5 years | Latanoprost (BAK)/ou | 2 months | NA | A, C, F |
| 10 | 75 | F | SS | 1st | Type II, ou | Latanoprost (BAK)/ou | 5 years | NA | NA | A, C, F | |
| 2nd | Type II, os | Latanoprost (BAK)/ou | 1 month | Dorzolamide/Timolol (BAK)/ou | 3 days | NA | A, B, D, F | ||||
| 11 | 70 | M | – | 1st | Type V, ou | Carteolol (BAK)/ou | 6 months | NA | NA | A, B | |
| 12 | 79 | M | – | 1st | Type II, ou | Timolol (BAK)/ou, Latanoprost (BAK)/ou | 5 years | NA | NA | A, C, F | |
| 13 | 79 | M | – | 1st | Type II, od | Latanoprost (BAK)/od | 1 year | Carteolol (BAK)/od | 2 months | NA | A, C, E, F |
| 14 | 96 | M | DED | 1st |
Type II, od Type V, os |
Carteolol (BAK)/ou | 3 years | NA | NA | A | |
| 15 | 78 | M | – | 1st | Type II, os | Brimonidine (purite)/os | 1 month | Dorzolamide (BAK)/os | 8 days | NA | C |
| 16 | 78 | M | DED | 1st | Type III, od | Brimonidine (purite)/ou, Dorzolamide/timolol (BAK)/ou | 1 month | NA | NA | B | |
| 2nd | Type II, ou | Carteolol(BAK)/ou | 1 year | NA | NA | B | |||||
| 17 | 70 | M | DED, DM | 1st | Type II, os | Latanoprost (BAK)/ou | 2 months | NA | NA | B, C | |
| 18 | 50 | M | AD | 1st | Type II, os | Brimonidine (purite)/ou dorzolamide/timolol (BAK)/ou | 5 years | NA | NA | A, C, F | |
| 19 | 91 | M | – | 1st | Type II, os | Latanoprost (BAK)/ou | 10 years | NA | NA | A |
M male, F female, DED non-Sjogren dry eye disease, BAK benzalkonium chloride, NA not-available, DM diabetic mellitus, SS Sjogren syndrome, AD atopic dermatitis.
aManagement type: A: preservative-free lubricant, B: TSCL, C: Stopped all glaucoma drugs, D: Stopped last-added glaucoma drugs, E: Shifted to oral anti-glaucoma medications, F: Shifted to preservative-free bimatoprost or carteolol (with BAK).